July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.
June 18, 2020: Existing evidence-based interventions aren't enough to close HIV's racial gap; transgender patient outcomes in the HIV care continuum; meeting long-term needs of formerly incarcerated people; acute respiratory illness severity and HIV status.
Ending the HIV Epidemic Is a Team Effort. The New York City and State Health Departments Discuss Their Combined Work
Johanne Morne, M.S., and Oni Blackstock, M.D., sat down with TheBody to discuss their successes and their work to close the disparities gap.
What Needs to Happen Before California Pharmacies Can Sell PrEP and PEP Without an Initial Prescription
Pharmacists will increasingly play a role in pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) access in California.
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.
Young people in the nation's capital are living in the middle of some of the worst structural and systemic inequalities in America. We should be helping them out.
Four recent studies in JAIDS chiefly focused on PrEP provision to cisgender women and gay and bisexual men.
Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.
HIV vaccine researchers are working to study and solve the problem, with a focus on how researchers themselves can more deeply build and earn trust.
PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.